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Abstract
Introduction—Hypothalamic-pituitary-adrenal (HPA) deregulation is commonly observed in 
cancer patients, but its clinical significance is not well understood. We prospectively examined the 
association between HPA activity, tumor-associated inflammation, and survival in ovarian cancer 
patients prior to treatment.
Materials and Methods—Participants were 113 women with ovarian cancer who provided 
salivary cortisol for three days prior to treatment for calculation of cortisol slope, variability, and 
night cortisol. Cox proportional hazard regression analyses were used to examine associations 
between cortisol and survival in models adjusting for disease stage, tumor grade, cytoreduction 
and age. On a subsample of 41 patients with advanced disease ascites fluid was assayed for levels 
of interleukin-6 (IL-6) and correlated with cortisol variables.
Results—Each cortisol measure was associated with decreased survival time, adjusting for 
covariates (all p<.041). A one standard deviation increase in night cortisol was associated with a 
46% greater likelihood of death. Patients in the high night cortisol group survived an estimated 
average of 3.3 years compared to 7.3 years for those in the low night cortisol group. Elevated 
ascites IL-6 was associated with each cortisol measure (all r >.36, all p<.017).
Discussion—Abnormal cortisol rhythms assessed prior to treatment are associated with 
decreased survival in ovarian cancer and increased inflammation in the vicinity of the tumor. HPA 
abnormalities may reflect poor endogenous control of inflammation, dysregulation caused by 
tumor-associated inflammation, broad circadian disruption, or some combination of these factors. 
Nocturnal cortisol may have utility as a non-invasive measure of HPA function and/or disease 
severity.
Keywords
Ovarian Neoplasms; Inflammation; Hydrocortisone; Chronobiology Disorders; Biological 
Markers
1. INTRODUCTION
Ovarian cancer is the second most commonly diagnosed gynecologic malignancy and the 
most deadly, with five year survival rates of 44% for all patients, and 27% for patients with 
metastatic disease (American Cancer Society, 2014). Recent research has demonstrated 
effects of neuroendocrine signaling on a variety of pathways implicated in ovarian tumor 
growth including angiogenesis, invasion, anoikis, and promotion of inflammation in the 
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tumor microenvironment (Cole & Sood, 2012). To date, mechanisms that have been 
characterized predominantly involve beta-adrenergic signaling. Neuroendocrine signals 
from the hypothalamic-pituitary-adrenal (HPA) axis regulate endogenous inflammation and 
metabolic activity, via the release of glucocorticoids (Tsigos & Chrousos, 2002). Although 
glucocorticoids are known to play a regulatory role in other cancers, little is known about 
the role of the HPA axis in the context of ovarian cancer.
Cortisol, a glucocorticoid, is released into circulation by the adrenal cortex following 
upstream signaling from the pituitary and hypothalamus (Rhen & Cidlowski, 2005). Cortisol 
follows a diurnal cycle; levels typically peak in the morning and reach a nadir during the 
second half of the night, though significant inter-individual differences are common even in 
apparently healthy people (Chrousos, 1995; Stone et al., 2001; Clow et al., 2010). Excess 
circulating cortisol provides negative feedback to the hippocampus and hypothalamus, 
however, under conditions of chronic inflammation the feedback system can become 
unresponsive, resulting in abnormal diurnal cortisol rhythms (Silverman & Sternberg, 2012).
Glucocorticoids have a variety of effects in cancer; they have been shown to inhibit 
apoptosis in breast, cervical and ovarian cancer cell lines and in animal models of breast 
cancer (Volden & Conzen, 2013). Incubation of ovarian cancer cells with cortisol has been 
shown to reduce expression of tumor-suppressor genes SLIT2 and ROBO1 (Dickinson et al., 
2011), as well as to suppress the cytotoxic effects of paclitaxel, a drug commonly used in 
ovarian cancer chemotherapy (Flint et al., 2009). Moreover, flattened diurnal cortisol 
rhythms have been linked to decreased survival in breast, lung, and renal cell carcinoma 
patients, adjusting for clinical and demographic characteristics (Sephton et al., 2000; Cohen 
et al., 2012; Sephton et al., 2013). For example, in a recent study of renal cell carcinoma 
patients, flatter cortisol slope was associated with an approximately two-fold greater 
likelihood of death (HR=1.9, 95% CI 1.3, 3.0) adjusting for a variety of disease 
characteristics (Cohen et al., 2012).
We have previously observed an altered cortisol diurnal rhythm in ovarian cancer patients 
prior to surgery compared to that of pre-surgical patients with benign disease and healthy 
controls not facing surgery. Ovarian cancer patients show elevated afternoon and nocturnal 
cortisol, resulting in blunted diurnal cortisol variability (Weinrib et al., 2010). These patterns 
of dysregulation have been associated with elevated measures of systemic inflammation in 
ovarian cancer patients (Lutgendorf et al., 2008; Schrepf et al., 2013). This inflammation is 
hypothesized to be tumor-derived (Edgell et al., 2010). Furthermore, inflammation in the 
tumor microenvironment is strongly linked to ovarian cancer progression (Kulbe et al. 
2012). Animal models have demonstrated that tumor growth can activate the HPA axis and 
induce systemic inflammatory signaling (Lamkin et al., 2011; Yang et al., 2014). However, 
HPA activity has not been investigated in the context of survival in ovarian cancer. 
Moreover, the relationship between HPA activity and inflammation measured in the vicinity 
of the tumor has not been previously characterized in the clinical setting of ovarian cancer.
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2. MATERIALS AND METHODS
2.1 Participants
Participants were 113 women at least 18 years of age, with no auto-immune disease or 
systemic steroid use (i.e. prednisone) and no previous history of cancer. Participants were 
eligible if histology confirmed primary invasive epithelial ovarian, primary peritoneal, or 
fallopian tube carcinoma. Patients were excluded if diagnosis was a primary cancer of 
another organ, an ovarian tumor of non-epithelial origin, a tumor of low malignant potential, 
or benign disease. Included patients had surgery at least one year prior to the date of 
censoring. (See Figure 1 for Consort diagram showing included patients). All procedures 
were approved by the Institutional Review Boards of the University of Iowa, the University 
of Miami and Mercy Medical Center in Miami, FL. The earliest date of surgery was in 
January of 2004 and all survival information was censored on June 15th, 2013, or on the last 
date of the last recorded follow-up.
2.2 Procedure
Participants were recruited sequentially from participating institutions during pre-surgical 
visits for pelvic/abdominal masses suspected for ovarian cancer. Participants completed 
demographic and psychosocial questionnaires and collected salivary cortisol three times 
daily for three days prior to surgery. Disease was staged as I-IV, grade as low or high, and 
histology as serous or non-serous tumor. Advanced stage disease (i.e. III-IV) refers to 
disease that has spread from the ovaries/fallopian tubes to the lining of the abdomen, 
adjacent organs, lymph nodes, or more distant sites. High grade tumor refers to tumor that is 
poorly differentiated and no longer resembles normal ovarian cells. Both advanced stage 
disease and high grade tumor are associated with poorer survival (American Cancer Society, 
2014). Tumors of serous histology are thought to primarily arise from the fallopian tubes 
and are the most common and one of the most aggressive forms of epithelial ovarian cancer 
(Kurman, 2013). Extent of cytoreduction was classified as optimal if no visible tumor 
remained following surgery or if the largest remaining nodule was less than 1 cm, or 
suboptimal if greater than 1 cm of tumor remained. Completeness of cytoreduction has been 
associated with increased survival in epithelial ovarian cancer (Bristow et al., 2002). All 
samples were examined by a gynecologic pathologist. Most patients went on to receive at 
least six cycles of platinum and taxane combination chemotherapy. Demographic 
information was extracted from participant responses and included marital status (single, 
divorced, widowed, separated; or married/living with partner), and level of education 
attained. Sleep was assessed by the Pittsburgh Sleep Quality Inventory (PSQI; Buysse et al., 
1989). Symptoms of depression were assessed by the Center for Epidemiologic Studies – 
Depression (CES-D) scale (Radloff, 1977). Disease symptoms, such as fatigue, nausea, and 
loss of appetite were measured using the Physical Well-Being (PWB) subscale of the 
Functional Assessment of Cancer Therapy (FACT) scale (Cella et al., 1993). Tobacco use 
was categorized as never a tobacco user or current/former tobacco user. Alcoholic beverages 
were coded as average weekly consumption. Clinical disease characteristics, histological 
information, and date/cause of death were extracted from medical records or state/national 
death indices where needed. Survival time was calculated as the number of days between 
date of tumor resection and date of death, censoring, or last recorded follow-up.
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2.3 Cortisol Collection
Salivary cortisol was collected by participants in provided salivettes three times daily for 
three days immediately prior to surgery. Participants were instructed to collect the first 
sample immediately upon waking, the second sample at 5pm (allowing at least thirty 
minutes after a meal), and the final sample at bedtime. Participants were instructed not to 
eat, consume caffeine, or exercise for thirty minutes prior to sample collection, and to place 
salivettes in the refrigerator at the end of the day. Participants wrote the time of collection on 
tubes and returned them prior to surgery. Self-report of collection has previously been 
shown to be a reliable method of assessment (Kraemer et al., 2006). Salivary cortisol is 
stable at room temperature and correlates well with serum cortisol levels (Kirschbaum & 
Hellhammer, 1994). Samples were assayed by chemiluminescence immunoassay (IBL, 
Hamburg, Germany) at the Technical University of Dresden. The lower detection limit is 
0.41 nmol/L, and inter-assay and intra-assay coefficients of variance are <10%.
2.4 Cortisol Analyses
All cortisol values were transformed by a natural logarithm to normalize their distribution. 
Cortisol slope, a measure of the hourly decrement in salivary cortisol concentrations over 
the course of the day, was calculated by regressing each of the 9 individual cortisol values 
on their time of collection. Cortisol variability was calculated as the magnitude of decrease 
from the earliest collection time point (approximating peak concentrations) to the night time 
point (closest to the nadir) or: ((Morning-Night)/Morning)*100, as described previously 
(Jehn et al., 2006). Night cortisol was calculated as a simple average of the night cortisol 
values for each patient. Greater cortisol variability and steeper (more negative) cortisol 
slopes are considered to be more normal cortisol profiles. Following recommended best 
practices for cortisol analyses, only values represented by at least two samples per time point 
(e.g. two morning, two afternoon, two night for calculation of slope) were included in the 
analyses, as a single day of collection is not considered reliable for salivary cortisol 
(Kraemer et al., 2006). The most frequently cited reason for incomplete collection was that 
patients were too preoccupied in preparation for surgery. Twenty one participants were 
excluded from cortisol analyses because of incomplete collection. However, as a 
conservative measure, models were also tested using all available cortisol data from patients 
who had incomplete collection. Samples collected outside an acceptable time frame were 
excluded, for purpose of homogeneity (waking sample: 0400h-0900h-, afternoon sample: 
1600h–1830h, night time sample:2000h–2400h). Three participants did not label their 
salivettes properly and were excluded, and 13 collected too many samples outside the 
acceptable time frames, resulting in too few collections to calculate cortisol values, and were 
excluded as well.
2.5 Cytokines
Ascites fluid was obtained during surgery from patients with advanced stage disease and 
high grade tumor during surgery (n=41). Plasma was drawn from all eligible patients willing 
and able to provide blood the morning of surgery (n=93). Blood and ascites were centrifuged 
at 1,126× g at 4°C for 15 minutes and frozen at −80°C until testing. Interleukin-6 (IL-6) was 
assayed in duplicate in ascites and plasma by ELISA (R & Diagnostics, Minneapolis, MN) 
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with results interpolated from the standard curve provided with the kits. The minimum 
detectable level is less than 0.7 pg/mL and inter-assay variability ranges from 3.3% to 6.4%. 
IL-6 levels in ascites are correlated with tumor levels and are thought to represent the 
amount produced by tumor (Burger et al., 1995). IL-6 values were not correlated with 
sampling time (r=0.12, p=.48).
2.6 Statistical Analyses
Analyses were performed with SPSS, version 21.0 (Armonk, NY). Cytokine values were 
log10 transformed to correct for non-normal distributions. To determine if cortisol values 
varied according to clinical and demographic characteristics, and to inform covariate 
selection, oneway Analysis of Variance (ANOVA)s and Pearson correlations were used. We 
also conducted multivariate General Linear Model (GLM) analyses with significant disease 
and demographic characteristics to determine which if any were most strongly associated 
with cortisol variables. GLMs allow for both continuous and categorical covariates to be 
tested simultaneously. ANOVA and Chi-square tests conducted on these variables to 
compare disease characteristics between participants included in the analysis and those who 
declined to participate, stopped collecting, or had data that could not be analyzed, to ensure 
representativeness. Stage was dichotomized into early (I-II) and late (III-IV) disease. Cox 
proportional hazard regression analyses were conducted to determine the univariate 
association of each clinical disease/treatment characteristic (stage, grade, optimal/
suboptimal cytoreduction, serous/non-serous tumor, presence of ascites fluid, # of cycles of 
chemotherapy initially received) and potential confounding demographic/psychosocial 
characteristics (BMI category, tobacco use, weekly alcohol consumption, age, sleep quality, 
physical well-being, and depression score) with survival time. Variables that were 
significant or approaching significance (p <.10) were retained in multivariate analyses that 
included the cortisol variables of interest. Median splits on cortisol variables were used in 
Kaplan-Meier curves for illustrative purposes. All models were evaluated for fit and 
adequacy (Singer & Willett, 2003). On a subsample of 41 patients with advanced stage-
disease and high-grade tumors (characteristics typical of a majority of our sample and most 
ovarian cancer patients) who had available ascites fluid, we conducted multiple regression 
controlling for age and BMI to test the association between IL-6 in ascites and the cortisol 
variables for the purpose of determining if dysregulated cortisol patterns were associated 
with inflammation in the vicinity of the tumor. Similarly, the association between circulating 
IL-6 and cortisol values was tested by General Linear Models controlling for age, disease 
stage (early vs. late), and tumor grade (low vs. high-grade tumor). The level of significance 
for all analyses was p < .05 and all relevant tests were two-sided.
3. RESULTS
3.1 Sample Characteristics
Patients were approximately 58 years old (on average) at the time of study entry, married/
living with a partner, and college educated. Demographic and clinical information is 
presented in Table 1. Patients who participated in the study did not differ significantly from 
those who declined to supply cortisol (n=49) on demographics (all p<.19) or disease 
characteristics including disease stage (p = .60), tumor grade (p = .84), cytoreduction (p = .
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50) tumor histology (p = .10), initial cycles of chemotherapy (p = .61), or survival (p = .66). 
When comparing all patients eligible but not included in the study (patients with exigent 
surgery, patients that declined to collect cortisol and patients with incomplete or unusable 
cortisol collection, n =135) there were no differences on any demographic variable (all p>.
12) except ethnicity, as a slightly higher proportion of patients not included were Hispanic 
(10% for patients not included vs. 3% of included patients, p = .022). Similarly there were 
no differences between included and not included patients on disease stage (p = .68), tumor 
grade (p = .42), cytoreduction (p = .92), initial cycles of chemotherapy (p = .99), or survival 
(p = .93). A slightly higher proportion of patients not included had serous vs. non-serous 
disease (81% of not included patients vs. 67% of included patients, p =.012). Of the 113 
ovarian cancer patients who participated, 53 died prior to the end of the study and 60 were 
censored on June 15th, 2013 or on the date of their most recent clinic visit if lost to follow-
up. Cause of death for the 53 patients who had died was persistent or recurrent ovarian 
cancer or complications associated with cancer disease and treatment. Median follow-up 
time was 2 years, 11 months (range: 1 day - 9 years, 4 months).
3.2 Demographics, Disease Characteristics, and Cortisol
Among the 113 patients for whom complete data was available, advanced age was 
associated with higher night cortisol (p=.004) but not variability (p=.14) or slope (p=.10). 
Late stage disease was associated with higher night cortisol (p=.005) and marginally 
associated with flattened slope (p=.07) and reduced variability (p=.09). High grade disease 
was associated with higher night cortisol, flattened slope and reduced variability (all p < .
046) but cortisol variables were not associated with histology (all p >.33; see Table 2). In 
multivariate GLMs including stage, grade, and serous/non-serous tumors only the 
association between high tumor grade and elevated night cortisol remained significant (p=.
013). Moreover, there were no significant associations between night cortisol, cortisol 
variability, or cortisol slope and demographic characteristics, BMI category, race, ethnicity, 
relationship status, education level, smoking status, alcohol consumption or sleep quality, or 
depression score (all p values >.11). Poorer physical well-being was associated with 
elevated night cortisol (p = .022), flattened cortisol slope (p = .042), and reduced cortisol 
variability (p = .005), similar to our previous investigation of somatic symptoms and 
salivary cortisol in ovarian cancer patients prior to treatment (Weinrib et al., 2010). Night 
cortisol was highly correlated with cortisol variability (r = −.727, p < .001) and slope (r = .
758, p < .001) , suggesting that night cortisol may be a reliable proxy for cortisol 
assessments that require more complex collection procedures. Diurnal slope and cortisol 
variability were also strongly associated (r = .880, p < .001).
3.3 Cortisol and survival
In univariate Cox proportional hazard regression analyses, advanced stage disease (p=.003), 
high grade tumor (p=.073), suboptimal cytoreduction (p=.037), and older age (p=0.001) 
were associated with shortened survival time, while serous histology and number of cycles 
of chemotherapy were not (all p>.13). BMI category, sleep quality, CES-D depression score, 
physical well-being, lifetime tobacco use and weekly alcoholic beverages were not 
significant predictors of survival (all p>.19) and thus were not retained in the final models. 
See Table 3 for univariate analyses. In the first multivariate Cox model controlling for 
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disease stage, tumor grade, cytoreduction, and age, elevated night cortisol levels prior to 
surgery were independently associated with shorter survival time (β=.375, H.R.=1.455, 95% 
CI=1.059, 1.998, p=.021). Thus, a patient whose nocturnal cortisol level was 2.22 (ln) 
nmol/L (one standard deviation above the mean) would have a 46% greater risk of death 
compared to a patient whose nocturnal cortisol was 1.44 nmol/L (the mean for in this 
sample). Kaplan-Meier curves based on a median split of night cortisol are shown for 
illustrative purposes (see Figure 2). These plots indicate that patients in the low night 
cortisol group survived an estimated median 7.3 years (95% CI =3.8, 10.8 years) compared 
to 3.3 years (95% CI=2.6, 3.8 years) for those in the high night cortisol group. Results for 
multivariate Cox regression models for cortisol variability and cortisol slope were very 
similar (cortisol variability: β= −.314, HR=.731, 95% CI=.570, .937, p=.013; cortisol slope: 
β=.325, HR=1.384, 95% CI=1.015, 1.886, p=.040). For example, a patient whose cortisol 
declined 91% (one standard deviation above the mean) throughout the day would have 29% 
lower risk of death compared to a patient whose salivary cortisol declined 69% throughout 
the day (the mean decline in this sample). See Figure 3. See Table 4 for all parameters in 
each model.1
3.4 Cortisol, Tumor-Associated Inflammation, and Circulating Levels Inflammation
Elevated night cortisol (β=.38, p=.029), flattened cortisol slope (β=43, p=.013) and reduced 
cortisol variability (β=−.43, p=.013) were each associated with higher levels of 
inflammation as indicated by higher levels of ascites IL-6. See Figure 4. Similarly, elevated 
night cortisol (β=.30, p< .001), flattened cortisol slope (β=.29, p < .001) and reduced cortisol 
variability (β= − .30, p < .001) were each associated with higher levels of circulating 
inflammation indicated by higher levels of plasma IL-6.
4. DISCUSSION
The key finding of this study is that dysregulated function of the HPA axis, evidenced by 
reduced diurnal cortisol variability, flattened diurnal cortisol slope, and elevated night 
cortisol, is associated with decreased survival time in ovarian cancer patients, controlling for 
relevant clinical and demographic covariates. This is the first study demonstrating that HPA 
function at the time of surgery is associated with significant differences in survival for 
ovarian cancer. It should be noted that cortisol levels were assessed prior to any treatment, 
indicating that HPA differences were not due to inter-individual responses to treatment or 
attendant aspects of treatment such as the use of glucocorticoids during chemotherapy. The 
relationship between cortisol dysregulation and overall survival does not appear to be 
mediated by sleep dysregulation, symptoms of disease, or depression, as none of these 
factors were associated with overall survival. These findings are consistent with prior 
research linking altered cortisol slope to shorter survival in breast, lung and renal cell cancer 
patients (Sephton et al., 2000; Cohen et al., 2012; Sephton et al., 2013). They are also 
consistent with previous experimental data demonstrating that invasive carcinomas can up-
1In supplemental analyses with all available cortisol data, including patients with incomplete collection, results were very similar: 
night cortisol, n=134, H.R.=1.339, 95% CI= 1.007, 1.779, p=.045; cortisol slope, n=122, H.R =1.313, 95% CI= .978, 1.762, p=.068; 
cortisol variability, n=122, H.R.=.784, 95% CI= .639, .962, p=.019. In secondary analyses including physical well-being as a 
covariate, the results were virtually unchanged: night cortisol, n=109, H.R.=1.542, 95% CI= 1.085, 2.191, p=.016; cortisol slope, 
n=109, H.R =1.436, 95% CI=1.027, 2.008, p=.034; cortisol variability, n=109, H.R.=.694, 95% CI= .526, .916, p=.010.
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regulate circulating glucocorticoid levels in animal models of human cancer as well as 
circulating levels of IL-6 (Lamkin et al., 2011; Yang et al., 2014). As each of the clinical 
studies adjusted for clinical factors including disease severity, these findings suggest that 
HPA function may play a role in disease progression and cancer survival or, alternately, may 
be a marker for disease-related processes, such as those related to inflammation or broader 
circadian disruption.
Analysis of IL-6 in ascites of a subsample of participants demonstrated that blunted diurnal 
cortisol variability, flattened slope, and elevated night cortisol were each associated with 
higher levels of this pro-inflammatory cytokine in the vicinity of the tumor, suggesting 
greater HPA dysregulation accompanies higher levels of tumor-associated inflammation. 
Ovarian cancer cells secrete pro-inflammatory cytokines, such as IL-6, IL-1β, and TNF-α, 
that promote invasion of, and attachment to, surrounding tissue, as well as angiogenesis and 
the activation of tumor associated macrophages (TAMs) to a tumorigenic phenotype, all of 
which are related to poorer survival (Offner et al., 1995; Obata et al., 1997; Jeannin, Duluc, 
& Delneste, 2011;;; Schauer et al. 2013). Higher levels of IL-6 in ascites have recently been 
associated with cell surface expression of CD163, a marker of TAMs, and shortened time to 
recurrence (Lane et al.,, 2011; Reinartz et al., 2014). Additionally, blunted variability and 
diurnal slope, as well as elevated night cortisol were each associated with higher IL-6 in 
plasma, confirming the results of earlier studies in our lab (Lutgendorf et al., 2008). It is 
notable that in both ascites and plasma, higher IL-6 was associated with elevated night time 
cortisol during the prior three days, the opposite effect that would be expected if cortisol was 
acting to suppress inflammation.
The relationship between tumor-associated inflammation and HPA function may be 
bidirectional, as sustained inflammatory signaling is believed capable of inducing alterations 
in HPA activity, and altered HPA activity can lead to reduced inflammatory control 
(Silverman & Sternberg, 2012). Each level of the HPA axis contains cytokine receptors and 
pro-inflammatory cytokines are capable of crossing the blood brain barrier and signaling the 
brain via the vagus nerve (Dantzer & Kelley, 2007). In vitro studies have demonstrated that 
pro-inflammatory cytokines exert a profound influence on glucocorticoid receptors (GRs) 
and their function, including downregulated GR-mediated gene transcription, reduced GR 
binding to Glucocorticoid Response Elements, and reduced GR translocation (Pace & 
Miller, 2009). Therefore, it is possible that dysregulated HPA rhythms indicate impairment 
of inflammatory control in the tumor microenvironment and associated risk factors such as 
polarization of macrophages to a tumorigenic phenotype, increased tumor vascularization, 
and enhanced invasive potential. However, it is not possible to determine in this 
observational study whether HPA dysregulation is secondary to tumor biology, or if HPA 
dysregulation contributes to the conditions favoring the development of aggressive tumor or 
both. Both pathways are biologically plausible.
Most ovarian cancer patients respond favorably to front-line treatment and achieve a period 
of disease remission, however, the development of drug resistant disease in subsequent 
recurrence is a major factor in survival (Sood & Buller, 1998). Interestingly, a recent study 
found that breast cancer cell lines incubated with cortisol demonstrated marked resistance to 
the effects of paclitaxel, a common front-line chemotherapeutic agent in the treatment of 
Schrepf et al. Page 9
Psychoneuroendocrinology. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
ovarian cancer, and this effect was reversed by co-incubation with a glucocorticoid receptor 
antagonist (Flint et al., 2009). Similarly, incubation of freshly isolated ovarian cancer cells 
with dexamethasone, a synthetic glucocorticoid, inhibited the apoptotic effects of cisplatin, a 
frontline platinum based chemotherapeutic agent used in the treatment of ovarian cancer. 
Additionally, cisplatin reduced tumor volume in nude mice xenografted with human ovarian 
cancer cells, but this effect was reversed when mice were co-treated with dexamethasone 
(Zhang et al., 2006). These findings suggest that dysregulated cortisol rhythms resulting in 
higher tonic exposure of tumor tissue to cortisol may contribute to the development of drug-
resistance disease.
The HPA diurnal cycle is tied to central regulatory mechanisms such as the suprachiasmatic 
nucleus of the hypothalamus that governs a broad range of biological functions. In ovarian 
cancer persistent sleep difficulties have been noted (Clevenger, et al. 2013), and significant 
differences in the expression of clock genes have been described in ovarian tumor tissue 
when compared to normal ovaries (Tokunaga et al., 2008). Cortisol has recently been shown 
to play a role in the synchronization of peripheral tissues with central mechanisms of diurnal 
regulation (Mavroudis et al., 2012). Therefore, HPA activity may be linked to broader 
circadian disruption, which has been linked to cancer incidence, progression and survival 
(Sephton, et al, 2013). In particular, inflammatory processes and circadian disruption are 
known to interact in ways which might influence survival outcomes. For instance, rest-
activity patterns measured by actigraphy are associated with levels of serum cortisol levels 
and cytokines in metastatic colorectal cancer patients. This suggests that altered circadian 
timing systems may promote loss of suppression of tumor-inflammation by the HPA axis, or 
vice versa (Rich et al. 2005). Additionally, as prior studies found diurnal rhythmicity to be 
associated with survival when cortisol is measured post-treatment, tumor inflammation is 
unlikely to explain the all the variation in HPA axis function. This variation may be 
attributable, in part, to more persistent variability in circadian timing systems (e.g. the 
expression of central clock genes; Sephton et al. 2000; Sephton et al. 2013;). In fact, 
disruption of core circadian rhythms, which HPA axis dysregulation may indicate, is 
associated with down-regulation of clock genes in peripheral cells, and this down-regulation 
has been demonstrated to accelerate tumor growth in experimental animal models of breast 
cancer (Yang et al., 2009). It is therefore possible that HPA dysregulation in ovarian cancer, 
and the associated increase in tumor-associated inflammation, represents suppression of 
cellular clocks at the level of tumor tissue.
4.1 Clinical Implications
Elevations in salivary cortisol sampled prior to bedtime were associated with higher grade 
tumors, a more pronounced inflammatory profile in ascites, and shorter survival time 
controlling for relevant clinical and demographic covariates. This raises the possibility that 
non-invasive sampling of nocturnal salivary cortisol may have potential as a biomarker of 
more refractory disease and help identify patients in need of specific treatment regimens, 
though more research is required to replicate these findings and explore their molecular 
correlates.
Schrepf et al. Page 10
Psychoneuroendocrinology. Author manuscript; available in PMC 2016 March 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
4.2 Limitations
It should be noted that these findings are correlational and thus limit causal inferences. 
Ultimately, pharmacologic inhibition of inflammatory mediators and glucocorticoid levels 
will be required to determine whether these dynamics have clinically relevant causal 
influences on ovarian cancer progression rates. Our sample was disproportionately 
Caucasian and non-Hispanic. As a slightly higher proportion of patients not included were 
Hispanic it is important for these findings to be replicated in a more diverse patient sample. 
Although a substantial number of patients declined or did not collect enough cortisol for 
analysis, the final sample appears to be broadly representative of the patient population and 
thus findings can be generalized, with caution (while a slightly higher proportion of patients 
not included had serous disease, this factor was not associated with survival).
4.3 Conclusions
HPA axis dysregulation prior to surgery was linked to post-surgical ovarian cancer survival, 
above and beyond the correlation of HPA axis activity with tumor grade and stage. HPA 
axis dysregulation is also correlated with both circulating and tumor-associated levels of the 
pro-inflammatory cytokine IL-6. As such, night time cortisol levels may provide a non-
invasive biomarker of ovarian cancer disease severity that isindependent of established 
pathological markers. The observation that all cortisol measures were strongly associated 
with one another suggests these measures are facets of a unitary construct representing 
cortisol dysregulation. Night cortisol may be a sufficient and parsimonious measure of HPA 
function for researchers interested in ovarian cancer populations.
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Figure 1. 
Flow chart of patient recruitment.
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Figure 2. 
Kaplan Meier survival curve for patients with high nocturnal cortisol (median 3.3 years, 
95% CI=2.6, 3.8 years) vs. patients with low nocturnal cortisol (7.3 years, 95% CI =3.8, 
10.8 years). Cox regression adjusted for covariates indicates that patients with lower 
nocturnal cortisol had longer survival times (p=.021).
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Figure 3. 
Kaplan Meier survival curve for patients with flat diurnal cortisol slope (median 3.2 years, 
95% CI=2.1, 4.3 years) vs. patients with steep diurnal cortisol slope (6.8 years, 95% CI 
=4.5, 9.0 years). Cox regression adjusted for covariates indicates that patients with steeper 
cortisol slopes had longer survival times (p=.040).
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Figure 4. 
Scatterplot of Interleukin-6 assayed in ascites fluid and diurnal cortisol variability.
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Table 1
Demographic characteristics.
Participants N=113 Mean, Median (S.D.)
Age 57.99, 59, (11.73)
CES-Depression Score 14.01,13, (8.76)
Pittsburgh Sleep Quality Inventory Score 7.18, 7, (3.56)
Physical Well Being Score 21.26, 22, (5.48)
Frequency (%)
Education
High school or less 35(31)
Some college/trade school 38(34)
College graduate 30(27)
Advanced degree 9(8)
Not answered 1(1)
Race
American Indian/Alaska Native 1(1)
Asian 1(1)
Black/African American 2(2)
White 108(96)
Not answered 1(1)
Ethnicity
Hispanic 3(3)
Non-Hispanic 109(97)
Not answered 1(1)
Relationship Status
Single 12(11)
Divorced 12(11)
Married 72(64)
Widowed 14(12)
Living with partner 3(3)
Body Mass Index category
<20 underweight 2(2)
20–25 normal 29(26)
25–30 overweight 44(39)
30–40 obese 32(28)
>40 morbidly obese 6(5)
Disease Stage
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Participants N=113 Mean, Median (S.D.)
Early 32(28)
Late 81(72)
Tumor Grade
Low 13(12)
High 100(89)
Cytoreduction
Optimal 82(73)
Suboptimal 31(27)
Histology
Serous 76(67)
Non-serous 37(33)
CES= Center for Epidemiologic Studies
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